Correlation of Allograft Weight to Recipient Body Weight Index on Renal Function in Kidney Transplantation

2016 ◽  
Vol 48 (2) ◽  
pp. 578-582 ◽  
Author(s):  
L. García-Covarrubias ◽  
C. Pliego ◽  
L. Bermudez ◽  
A. Cicero ◽  
J. Cancino ◽  
...  
1980 ◽  
Vol 37 (12) ◽  
pp. 2266-2271 ◽  
Author(s):  
Donald R. Gunderson

Theory on r-K selection is used as a basis for examining correlations between instantaneous rate of natural mortality (M), gonad-body weight index, age at maturity, longevity, and Bertalanffy growth parameters (k, L∞) for 10 species of marine fish. All correlations were consistent with r-K selection theory. The gonad-body weight index was found to be more highly correlated with M than any of the other life history parameters examined (r2 = 0.62), and stepwise multiple regression showed that additional variables added little to the predictive ability of the model. The gonad-body weight index appears to be quite useful in predicting M, and development of an analogous index on an energetics basis might enhance its utility in this regard.Key words: natural mortality, r-K selection, life history parameters


2012 ◽  
Vol 47 (3) ◽  
pp. 295-299 ◽  
Author(s):  
Jie Bai ◽  
Lei Zhang ◽  
Xiao Hu ◽  
Yangping Xue ◽  
Fenglei Long ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Adamantia Mpratsiakou ◽  
Marios Papasotiriou ◽  
Konstantinos Tsiotsios ◽  
Theodoros Ntrinias ◽  
Evangelos Papachristou ◽  
...  

Abstract Background and Aims New onset diabetes (NODAT) is a common complication after kidney transplantation. The available treatment options in this patient population have limitations due to reduced renal function, possible interactions with immunosuppressive drugs and side effects such as hypoglycemic events. The aim of this study was to investigate the long term safety and efficacy profile of dipeptidyl peptidase-IV (DDP-4 inhibitors) administration in renal transplant recipients with NODAT. Method The study included 12 patients treated with DPP-IV inhibitors monotherapy as well as 5 patients receiving insulin monotherapy as initial treatment immediately after NODAT diagnosis. All patients were monitored at every scheduled outpatient visit and for 12 months after diagnosis by measuring glycosylated hemoglobin (HbA1c), serum creatinine (eGFR calculation with CKD-EPI formula), plasma immunosuppressive trough levels, serum lipids, blood pressure, and body weight. The mean values of the aforementioned parameters for the last six months of follow up were compared to the ones at diagnosis. Results Patients receiving DPP-IV inhibitors were treated with either linagliptin (4 patients), sitagliptin (4 patients), vildagliptin (2 patients) or halogliptin (2 patients). These patients had a mean age of 59.4 ± 12 years, a mean HbA1c of 6.6% and a mean fasting glucose of 114.5 mg/dl at diagnosis. The mean HbA1c the last 6 months of one year of follow up after initiation of treatment, decreased to 6.1% (p=0.03). Renal function remained stable (mean eGFR from 58.8 to 61.7 ml/min/1.73m2, p=ns) while plasma tacrolimus levels did not appear to be affected (from 6.2 to 5.5 ng/dl, p=ns). Patients received a slightly reduced mean dose of tacrolimus during the last six months of follow up in comparison to the one at initiation of treatment (from 2.9 to 2.6 mg/24h, p=ns). No significant difference was shown in serum total, LDL, and HDL cholesterol before and after treatment, nevertheless, triglyceride levels were significantly reduced (from 214.4 to 174.9 mg/dl, p=0.0039). A decrease in body weight was observed (from 79.9 to 77.9 kg, p=ns) which was however not statistically significant. Finally, achieving the goal of lowering HbA1c levels was better in patients treated with DPP-IV inhibitors than in those treated with insulin (6.1% vs 7.1%, respectively, p=0.01). Conclusion Administration of DPP-IV inhibitors appears to be a safe and effective option for the treatment of NODAT in renal transplant recipients with the benefit of avoiding hypoglycemic episodes and possibly better diabetes control than with insulin therapy.


2012 ◽  
Vol 4 (3) ◽  
pp. 170 ◽  
Author(s):  
Sreenivasan Sasidharan ◽  
YuetPing Kwan ◽  
LachimananYoga Latha ◽  
Mohammad AbuBasma Rajeh ◽  
Zuraini Zakaria ◽  
...  

1993 ◽  
Vol 69 (01) ◽  
pp. 045-049 ◽  
Author(s):  
Kurt Huber ◽  
Renate Beckmann ◽  
Peter Probst ◽  
Friedrich Rauscha ◽  
Fritz Kaindl ◽  
...  

SummaryWe studied 35 consecutive patients with short onset of myocardial infarction who underwent thrombolytic therapy with rt-PA at a standard dosage regimen of 100 mg rt-PA total (10 mg given as a bolus followed by 50 mg, 20 mg and 20 mg per hour for 3 hours). These patients were monitored for t-PA antigen and t-PA activity and PAI-1 activity plasma levels during rt-PA infusion. Success or failure of thrombolytic therapy was evaluated by non-invasive criteria (early plasma creatine kinase peaks, early peak plasma myoglobin values, and electrocardiographic criteria) as well as by means of coronary angiography at the fourth day after thrombolytic treatment. In 24 (68.6%) of these patients a success of thrombolytic therapy could be established by these criteria, while 11 patients did not respond to thrombolytic therapy. Fifteen patients (14 responders and one non-responder) had to be excluded from the further evaluation because in these patients clinical laboratory data obtained upon admission before initiation of thrombolytic therapy were not complete. Therefore, 20 patients (10 responders and 10 non-responders) could further be analysed. The two groups of patients were not significantly different in body weight, body weight index, age, gender, liver or kidney functional parameters as determined before initiation of the thrombolytic therapy. Furthermore, PAI-1 plasma levels before initiation of thrombolytic therapy were not significantly different in the two groups, as were rt-PA dosage per body weight or body weight index. Only heart rate and calculated cardiac output and cardiac index were significantly higher in the group of patients not responsive to thrombolytic therapy. t-PA values, however, at 30, 60 and 90 min after initiation of rt-PA infusion were significantly higher in the group of responders as compared to the group of non-responders. From these data we conclude that cardiac output which in turn determines liver blood flow might lead to different t-PA plasma levels following the same rt-PA dosage and the resulting t-PA plasma level might determine success or failure of thrombolytic therapy in respect to reopening of the infarct-related vessel.


2018 ◽  
Vol 39 (suppl_1) ◽  
pp. S5-S5 ◽  
Author(s):  
M V Purvis ◽  
L J Lindsey ◽  
C Leonard ◽  
A C Lintner ◽  
V Scott ◽  
...  

Pharmacology ◽  
2019 ◽  
Vol 103 (5-6) ◽  
pp. 291-302 ◽  
Author(s):  
Ying Fan

Background/Aims: Rhapontigenin (RPG) is a stilben derivative and is known to bear several effects such as antiallergic, anticoagulative, hypoglycemic, antiangiogenic, and purgative. The investigation was conducted to evaluate the cardioprotective efficacy of RPG in rats having acute myocardial infarction (MI) induced by isoproterenol (ISO). Methods: Animals were divided into 6 groups: group I (control group), group II (ISO-treated), group III (1.0 mg/kg/day RPG and ISO-treated), group IV (2.5 mg/kg/day RPG and ISO-treated), group V (5.0 mg/kg/day RPG and ISO-treated), and group VI (treated with RPG 5.0 mg/kg/day). Various cardiac stress markers, including infarct size and heart/body weight index, were investigated in animals with ISO-induced MI, such as inducible nitric oxide synthase (iNOS), creatinine kinase (CK), lactate dehydrogenase (LD), cardiac troponin-T (CTT), superoxide dismutase (SOD), and malondialdehyde. INOS, p38, caspase-3, and connexin 43 expressions were analyzed in animals. Inflammatory mediators, tissue necrosis factor-α (TNF-α) and interleukin-6 (IL-6), were detected in serum of experimental animals. Results: Group I animals indicated normal levels of biochemical parameters, whereas group II animals indicated high levels of these parameters and successful induction of MI. Pretreatment of animal groups III, IV, and V with RPG revealed amelioration of infarct size, heart/body weight index, CK, LD, CTT in rats, whereas group VI animals were treated only with RPG (5.0 mg/kg/day) and not with ISO. Levels of TNF-α, IL-6, MD, SOD, p38, and iNOS expressions were significantly downregulated by RPG administration (5.0 mg/kg/day). Conclusion: RPG ameliorates MI caused by ISO in rats and provides cardioprotective effect, via anti-inflammatory, antioxidant, and antiapoptotic effect.


Author(s):  
Lada Smelysheva ◽  
Alexander Kuznetsov ◽  
Ekaterina Musikhina ◽  
Galina Kovaleva ◽  
Natalya Artenyan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document